Derivatives of pyridinones were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity and prevent the spread of HIV-1 infection in cell culture without an appreciable effect on other retroviral or cellular polymerases. 3-{[(4,7-Dimethyl-1,3-benzoxazol-2-yl)methyljamino}-5-ethyl-6methylpyridin-2(LH)-one (L-697,639) and 3-{[(4,7-dichloro-1,3-benzoxazol-2-yl)methylJamino}-5-ethyl--methylpyridin-2(IH)-one (L-697,661) Infection with the human immunodeficiency virus type 1 (HIV-1) causes progressive destruction of the immune system, which ultimately results in AIDS. An essential step in the life cycle of HIV-1 is reverse transcription of the viral RNA genome to produce a double-stranded DNA copy. This process is mediated by the virally encoded reverse transcriptase (RT). Thus, RT is a potential therapeutic target and, indeed, nucleoside analog inhibitors of RT, such as 3'-azido-3'-deoxythymidine (AZT) and dideoxyinosine (ddI), are clinically effective drugs for treating HIV-1 infection (1, 2). However, their effectiveness is limited by toxicities, which may reflect inhibition of cellular polymerases and/or alteration of nucleoside pools, given that the nucleoside analogs are phosphorylated (in competition with natural nucleosides) to their active form by cellular kinases (3, 4). The emergence of AZT-resistant virus (5) further emphasizes the need to develop selective RT inhibitors that can be used either alone or in combination with nucleoside analogs. The development of specific RT inhibitors is the subject ofthis communication. (L-697,661) were synthesized by alkylation of 3-amino-5-ethyl-6-methylpyridin-2(1H)-one with either N-hydroxymethylphthalimide or the appropriate 2-halomethylbenzoxazole. Requisite aminopyridinone was obtained from condensation of 3-formyl-2-pentanone with nitroacetamide followed by catalytic reduction.
Infection with the human immunodeficiency virus type 1 (HIV-1) causes progressive destruction of the immune system, which ultimately results in AIDS. An essential step in the life cycle of HIV-1 is reverse transcription of the viral RNA genome to produce a double-stranded DNA copy. This process is mediated by the virally encoded reverse transcriptase (RT). Thus, RT is a potential therapeutic target and, indeed, nucleoside analog inhibitors of RT, such as 3'-azido-3'-deoxythymidine (AZT) and dideoxyinosine (ddI) , are clinically effective drugs for treating HIV-1 infection (1, 2) . However, their effectiveness is limited by toxicities, which may reflect inhibition of cellular polymerases and/or alteration of nucleoside pools, given that the nucleoside analogs are phosphorylated (in competition with natural nucleosides) to their active form by cellular kinases (3, 4) . The emergence of AZT-resistant virus (5) further emphasizes the need to develop selective RT inhibitors that can be used either alone or in combination with nucleoside analogs. The development of specific RT inhibitors is the subject ofthis communication.
METHODS
Chemical Synthesis of RT Inhibitors. The aminomethylene derivatives 5-ethyl-6- (L-697,639) , and 3-{[ (4,7- dichloro-1,3-benzoxazol-2-yl)methyl]amino}-5-ethyl-6-methylpyridin-2(1H)-one (L-697,661) were synthesized by alkylation of 3-amino-5-ethyl-6-methylpyridin-2(1H)-one with either N-hydroxymethylphthalimide or the appropriate 2-halomethylbenzoxazole. Requisite aminopyridinone was obtained from condensation of 3-formyl-2-pentanone with nitroacetamide followed by catalytic reduction.
Synthesis of ethylene derivative 5-ethyl-6-methyl-3-(2-phthalimidoethyl)pyridin-2(1H)-one (L-693,593) began with the condensation of 3-formyl-2-pentanone and cyanoacetamide to give 3-cyano-5-ethyl-6-methylpyridin-2(1H)-one. Reaction of this cyanopyridinone with POCl3 followed by methanolysis and reduction with diisobutylaluminum hydride led to 5-ethyl-2-methoxy-6-methylpyridine-3-carboxaldehyde. The aldehyde function was treated with trimethylsilyl cyanide, and the resulting cyanohydrin was reduced with lithium aluminum hydride to the amino alcohol. After conversion of the amino group to phthalimide, demethylation ofthe 2-methoxy group and alcohol dehydration was accomplished in one step by heating with pyridine hydrochloride. Catalytic reduction of the olefin formed yielded ethylene analog L-693,593. The structures of all pyridinones synthesized are consistent with their NMR spectra, and all compounds gave an acceptable combustion analysis (within 0.4%).
H1V-1 RT Assays. rC-dG. Other Enzyme Assays. Recombinant HIV-2 RT assays were done by using the HIV-1/rC-dG conditions. Simian immunodeficiency virus (SIV) strain mac251 was lysed in a buffer containing 0.1% Triton X-100, sonicated, and added to assays under the HIV-1 RT/rA-dT assay conditions. Avian myeloblastosis virus (AMV) RT (Molecular Genetic Resources, Tampa, FL) assays were done under the HIV-1/rC dG assay conditions. Moloney murine leukemia virus (Mo-MLV) was propagated in NIH 3T3 cells, and 10 ,ul of supernatant fluid was added to assays as described (8) . Calf thymus DNA polymerase a was purified by immunoaffinity chromatography (9) and assayed as described (7). HeLa cell DNA polymerase assays were done under standard conditions with the following divalent cations/template-primers: (i) P, 0.5 mM MnCI2/dA dT; (it) y, 0.5 mM MnCI2/rA dT; and (iii) 8 [3HJL-697,639 Binding Studies. The 120-,ul reaction mixture contained 50 mM Tris HC1 (pH 8.2), 100 mM KCI, 6 mM MgCl2, 0.2% polyethylene glycol (Mr -8000), 10 mM dithiothreitol, rC-dG at 14.7 ,g/ml, 20 uM dGTP, 100 nM [3H]L-697,639 (2.9 Ci/mmol). The reaction was initiated with 10 nM HIV-1 RT and incubated at 37°C for 20 min. After incubation, a 100-,u aliquot of the reaction mixture was withdrawn and applied to a 1-ml Sephadex G-50 spin column equilibrated in assay buffer and immediately centrifuged for 2 min at 2000 x g at ambient temperature (=25°C). For columns that were not prespun, the elution volume was 600-650 Al (prespin had no effect on results). Aliquots were removed to determine total radioactivity as well as total enzyme activity (using rA-dT system; 2.4 sec-1 = turnover number) as an indicator of total RT recovery. Enzyme recovery ranged from 25-50% under these conditions in several experiments, and the results were normalized to individual enzyme recovery determinations. Antiviral Assays. H9 human T-lymphoid cells (11) (17); and RUTZ. The antiviral potency against the patient isolates A018A/H112-2 and A018C/G910-6 (5) was determined in CEM cells (18) . These assays were similar to those using MT4 cells.
Synergy. The antiviral potencies (MT4 cells/HIV-1 strain IIIb) of combinations of inhibitors were analyzed for potential synergism by the method of Elion et al. (19) . Fractional inhibitory concentrations were derived and plotted, as described. Data were also analyzed using the median effect principle (20) . and 830 90 nM with the rC-dG, dA-dT, and rA-dT templateprimers, respectively. These compounds, therefore, inhibit both RNA-directed and DNA-directed DNA synthesis. The observation that inhibitory potency was a function of the composition of the template-primer (at similar ratios of template-primer concentration to their respective Km values) suggests that the pyridinones inhibit RT by binding to enzyme-template-primer complexes. Studies of the inhibition of HIV-1 RT by L-697,639 with rC dG revealed nonlinear progress curves (data not shown), consistent with that expected for a slow-binding, reversible inhibitor (21, 22) . Preincubation of enzyme with rC-dG and L-697,639 for 5 min resulted in linear progress curves (data not shown). Reversible inhibition was directly demonstrated by the observation that removal of inhibitor (500 nM) from a reaction mixture (by dilution or Sephadex G-25 chromatography) resulted in total restoration of RT activity. Reversephase chromatography of a complete reaction mixture containing equimolar (500 nM) concentrations of enzyme and L-697,639 yielded only unchanged L-697,639, indicating that, unlike AZT triphosphate and dideoxynucleoside triphosphates, L-697,639 does not undergo an enzymatically catalyzed transformation. Lineweaver-Burk analysis of the limiting steady-state velocities as a function of dGTP at various L-697,639 concentrations indicated the inhibition was noncompetitive with respect to dGTP (apparent K3 = 10 nM) and was also noncompetitive with respect to rC-dG templateprimer (data not shown). Moreover, using globin mRNA-dT as the template-primer, noncompetitive inhibition was observed with all four deoxynucleoside triphosphates. In contrast to the time-dependent inhibition observed with rC-dG, time-dependent inhibition was not apparent with rA-dT. to HIV-1 RT under steady-state conditions was found to be saturable (0.9 ± 0.2 mol/mol of heterodimer) and linearly dependent upon RT concentration; the approximate halfmaximal binding concentration was 20 ± 10 nM. Direct observation of slow binding ( Fig. 2A) 
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this rate constant for the approach of the steady-state velocity to its final value in the presence of 50 nM L-697,639. Studies of displacement of [3H]L-697,639 by unlabeled inhibitor yielded a value of 0.08 ± 0.02 min-1 (ti,2 9 min) for the first-order rate constant for dissociation of L-697,639 from the enzyme-template-primer-inhibitor complex (Fig. 2B) . The putative pyrophosphate analog, phosphonoformate (PFA) displaced [3HJL-697,639 from RT complexes when present in reaction mixtures initiated with RT ( Fig. 2A) as well as when added to reaction mixtures containing preformed [3H]L-697,639 RT complexes (Fig. 2B) . PFA appeared to decelerate and not accelerate the dissociation rate of [3H]L-697,639-RT complexes (Fig. 2B) . The current data base is insufficient to determine whether the displacement of [3H]L-697,639 from RT complexes, mediated by PFA, involves allosteric or direct (via partial overlap of the respective binding sites) interactions. Further studies are required to determine the role of Mg2+ (Fig. 1) In H9 human T-lymphoid cell culture, infected before treatment with inhibitor (Table 2 ), these compounds inhibited the spread of HIV-1 strain IIIb infection (CIC95) at 100 and 200 nM, respectively. These potencies are comparable to those reported in Table 1 , where inhibitor was added before infection. In MT4 human T-lymphoid cells, both compounds displayed CIC95 values of 25-50 nM (Table 2) . L-697,639 and L-697,661 were also active in phytohemagglutinin-stimulated human peripheral blood lymphocytes maintained in interleukin 2, where CIC90 values of 100 nM and 50 nM, respectively, were obtained. Thus, these compounds are potent in the primary target cells of the virus. In contrast to AZT (23) , the potency of the pyridinone inhibitors did not vary substantially among cell types. This difference may derive from the requirement that AZT, unlike L-697,639 or L-697,661, be activated by the host cell. In addition to the antiviral activity against HIV-1 strain IlIb, L-697,639 and L-697,661 were comparably potent against several diverse laboratory strains of HIV-1 and against two primary patient isolates ( Table 2 ). The two clinical isolates, A018A/H112-2 and A018C/G910-6, are AZT-sensitive and AZT-resistant viruses, respectively, from an AZT-treated individual (5). These viruses remained sensitive to L-697,639 and L-697,661. Consistent with the specificity of the pyridinone inhibitors toward HIV-1 RT, these compounds did not inhibit SIV.,251 infection in cell culture, nor were they cytotoxic at concentrations as high as 60 AM.
Because the mode of action of the pyridinone RT inhibitors differs from that of nucleoside analogs, we were prompted to determine the potential for interactions between compounds of these classes. Combinations of L-697,639 and AZT or ddI were prepared, and the antiviral potencies of these mixtures were determined in MT4 cell culture with HIV-1 strain 1HIb. These analyses indicated substantial synergism in the combined use of L-697,639 and either AZT or ddI (Fig. 3) . The cooperativity indices (19) were each -0.5. Similar indices were obtained on Proc. Nati. Acad. Sci. USA 88 (1991) analysis by using the median effect principle of Chou and Talalay (20) . Experiments using L-697,661 revealed comparable synergism with the two nucleoside analogs.
Recently, two other groups have identified submicromolar, HIV-1-specific, nonnucleoside RT inhibitors, R82150 (24) and BI-RG-587 (25) , which are structurally distinct from those reported here. Using the HIV-1 RT assays with rC dG, dA-dT, and rA-dT, we observed that BI-RG-587 had IC50 values of 73, 47, and 3920 nM, respectively, and R82150 had IC50 values of 70, 110, and 5100 nM, respectively. This pattern of template-primer selectivity is similar to that exhibited by the pyridinone compounds. In contrast to previous results showing that R82150 was not a potent inhibitor of polymerization with dC-dG (26) , the present data with dA-dT demonstrate that all three chemical classes are potent inhibitors of DNA-directed DNA synthesis. BI-RG-587 and R82150 also displaced [3H]L-697,639 from the HIV-1 RTtemplate-primer complex. These results suggest that the three groups of specific HIV-1 RT inhibitors may be structurally diverse members of a common pharmacological class. This conclusion was independently obtained from experiments demonstrating that RT from HIV-1 resistant to L-693,593 was resistant to L-697,639, L-697,661, BI-RG-587, and R82150 but not nucleoside analog triphosphates or PFA (27) .
Safety and tolerability studies with L-697,639 and L-697,661 have been initiated in humans. In studies to determine whether the potential exhibited by these pyridinones will be realized clinically, the demonstration of synergism in cell culture with combinations of these compounds and nucleoside analogs is important. In addition to benefits that may accrue in increased efficacy and reduced toxicity, the concurrent use of these agents with nucleoside analogs may ultimately prove most useful in minimizing the likelihood of the emergence of drug-resistant virus variants.
